THERAMetrics holding AG (SIX: TMX) and its fully owned subsidiary, Pierrel Research International AG (PRINT), announce €5 Million New Business (Contracts) signed in December 2013

Stans, Switzerland, December 18, 2013 - Ms Maxime Stevens, Group CEO of Pierrel Research International AG announces that, as anticipated in our press release of December 9th, 2013, an additional approximate €5 Mil of business has already been signed this month. This added to the already awarded approximately €10Mil in new contracts and amendments during the last eight months brings the total to €15 Mil to date. This reflects the significant strides of improvement already achieved in the last few months by the Group as an entirety; and the measures of support and confidence rewarded by the Sponsors. The PRINT pipeline for the Group continues to exceed €35 Mil, since additional new proposals are being developed in-house, in preparation for delivery as of January 2014. The backlog (future revenues secured by signed contracts) has now risen in excess of €21 Mil, with projects ongoing until 2019. About THERAMetrics THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland). For further information please contact THERAMetrics holding AG Investor and External Relations Tel.: +41 79 285 37 81 [email protected] www.therametrics.com

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.